Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Effective?

Diabetic macular oedema (DMO) is a common ocular problem among patients with diabetic retinopathy, which is sight-threatening and leads to blindness. The gold standard treatment for DMO had been focal/grid laser photocoagulation that achieved stabilisation of disease progression. However, newer phar...

Full description

Bibliographic Details
Main Authors:	Kuan Hao Yee, Srinivasan Sanjay
Format:	Article
Language:	English
Published:	European Medical Journal 2017-10-01
Series:	European Medical Journal Diabetes
Subjects:	efficacy read-2 bolt da vinci drcr protocol t diabetic retinopathy bevacizumab aflibercept pegaptanib laser ranibizumab diabetic macular oedema anti-vascular endothelial growth factor
Online Access:	https://www.emjreviews.com/diabetes/article/anti-vascular-endothelial-growth-factor-therapy-in-diabetic-macular-oedema-is-it-effective/

Similar Items

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?
by: Kuan Hao Yee, et al.
Published: (2017-10-01)

ANGIOGENESIS IN PROLIFERATIVE DIABETIC RETINOPATHY: RERSPECTIVES OF ANTI-VEGF THERAPY (REVIEW OF LITERATURE)
by: V. I. Konenkov, et al.
Published: (2015-12-01)

Primary treatment of diabetic macular edema
by: Tushar M Ranchod, et al.
Published: (2009-02-01)

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
by: J. M. Ruiz-Moreno, et al.
Published: (2020-09-01)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)

Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema
by: Milagros Mateos-Olivares, et al.
Published: (2021-07-01)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016-08-01)

An overview on age related macular degeneration and recent advances in its management
by: SOBIA N., et al.
Published: (2014-03-01)

Anti-VEGF agents in the treatment of diabetic macular edema
by: Vladimir Iosifovich Konenkov, et al.
Published: (2013-12-01)

Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
by: Science eProduction Office
Published: (2016-06-01)

Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
by: Chiara Bianca Maria Platania, et al.
Published: (2015-10-01)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
by: Veritti D, et al.
Published: (2021-01-01)

Aflibercept for diabetic macular oedema: a Meta-analysis of randomized controlled trials
by: Chu Luan Nguyen, et al.
Published: (2018-06-01)

Indicators of Visual Prognosis in Diabetic Macular Oedema
by: Sagnik Sen, et al.
Published: (2021-05-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
by: Kern C, et al.
Published: (2020-02-01)

Comparison of the efficacy of aflibercept and ranibizumab after a 3-month loading dose in patients with diabetic macular edema
by: Murat Çakmaklıoğulları, et al.
Published: (2021-03-01)

Should we consider pars plana vitrectomy in the primary treatment of diabetic macular edema?
by: Lihteh Wu, et al.
Published: (2017-01-01)

Should We Consider Pars Plana Vitrectomy in the Primary Treatment of Diabetic Macular Edema?
by: Lihteh Wu, et al.
Published: (2017-04-01)

The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs
by: Berker Bakbak, et al.
Published: (2016-01-01)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
by: Irini Chatziralli, et al.
Published: (2021-07-01)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017-03-01)

Outcomes of three intravitreal injections of bevacizumab given monthly for diabetic macular oedema is a viable treatment for an economically disadvantaged population
by: Aazambir S. Brar, et al.
Published: (2021-04-01)

Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
by: Lihteh Wu, et al.
Published: (2019-01-01)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
by: James F. Young, et al.
Published: (2019-07-01)

Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema
by: Gabriel Willmann, et al.
Published: (2017-05-01)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
by: Yue Zhao, et al.
Published: (2018-08-01)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
by: Benjamin Chi-Lan Yang, et al.
Published: (2019-01-01)

Treatment Strategies for Chorioretinal Vascular Diseases: Advantages and Disadvantages of Individualised Therapy
by: Michael W. Stewart
Published: (2016-10-01)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
by: William Fusi-Rubiano, et al.
Published: (2018-02-01)

Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation
by: Yan PS, et al.
Published: (2016-04-01)

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
by: Stacey A. Strong, et al.
Published: (2016-09-01)

The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice
by: Hussain Nazimul, et al.
Published: (2007-01-01)

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model
by: Cem Küçükerdönmez, et al.
Published: (2013-04-01)

Risk factors influencing the treatment outcome in diabetic macular oedema
by: Gupta Amod, et al.
Published: (1996-01-01)

Factors Influencing Response to Aflibercept in Diabetic Macular Oedema Patients in a Diverse North West London Population: A Real-World Study
by: Sim SY, et al.
Published: (2021-05-01)

Retina spotlight: Diabetic retinopathy - Preferred practice patterns
by: Syed Asghar Hussain, et al.
Published: (2017-01-01)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
by: Mahmoud Alaa Abouhussein, et al.
Published: (2021-01-01)

Prospects for the treatment of diabetic retinopathy: Modulation of endothelial growth factor
by: Anatoliy Gennad'evich Kuzmin, et al.
Published: (2009-06-01)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
by: Tariq Al-Debasi, et al.
Published: (2017-04-01)

Cannot write session to /tmp/vufind_sessions/sess_59r0lbct3nhq7hprv7149ruidq